C Foster, A Judd, H Lyall, T Dunn, K Doerholt, P Tookey, D Gibb For Young people with perinatally acquired HIV: a Transitioning UK cohort.

Slides:



Advertisements
Similar presentations
HYPnet Late presentation of vertically transmitted HIV infection in adolescence A Judd 1, R Ferrand 2,3, E Jungmann 2, C Foster 4, H Lyall 4, Brian Rice.
Advertisements

Children and resistance to HIV: CHIPS data Dr Katherine Boyd on behalf of Collaborative HIV Paediatric Study (CHIPS) and the UK HIV Drug Resistance Database.
The effect of changes in Kenya HIV guidelines on proportion of patients on ART and patient characteristics at initiation in Lumumba Health Centre, Western.
Retention across the continuum of care in a cohort of HIV infected children in rural India G. Alvarez-Uria RDT Hospital, Department of Infectious Diseases,
Data from the Collaborative HIV Paediatric Study (CHIPS) Reports up to March 2014* * Numbers are based on reports received rather than children seen to.
Feedback from Pregnancy research group UK CHIC / UK HIV Drug Resistance Database Meeting, 2 July 2010 Pregnancy Group: Jane Anderson, Loveleen Bansi, Susie.
Persisting long term benefit of genotypic guided treatment in HIV infected patients failing HAART and Importance of Protease Inhibitor plasma levels. Viradapt.
Validating five questions of antiretroviral non-adherence in a decentralized public-sector antiretroviral treatment program in rural South Africa Krisda.
Uptake of antiretrovirals in a cohort of women involved in high risk sexual behaviour in Kampala, Uganda J.Bukenya, M. Kwikiriza, O. Musana, J. Ssensamba,
Africans and HIV in the UK: an epidemiological perspective Nov 2006 Tim Chadborn On behalf of the HIV Reporting Section with special thanks to Julia Abernethy.
Long term follow up of the UK and Ireland paediatric cohort as teenagers transition to adult services Ali Judd, 1 Caroline Foster, 2 Caroline Sabin, 3.
Data from the Collaborative HIV Paediatric Study (CHIPS) Reports up to March 2013* * Numbers are based on reports received rather than children seen to.
Global HIV Resistance: The Implications of Transmission
Older and wiser: continued improvements in clinical outcome and highly active antiretroviral therapy (HAART) response in HIV-infected children in the UK.
Data from the Collaborative HIV Paediatric Study (CHIPS) Reports up to March 2009* * Numbers are based on reports received rather than children seen to.
Characteristics and responses to ART in the CHIPS cohort, Katja Doerholt and Ali Judd on behalf of the Collaborative HIV Paediatric Study (CHIPS)
Transition Program of HIV-infected adolescents to Adult HIV care in Buenos Aires, Argentina S. Arazi Caillaud 1, D. Mecikovsky 1, A.Bordato.
Data from the Collaborative HIV Paediatric Study (CHIPS) Reports up to May 2005.
HIV and STI Department, Health Protection Agency - Colindale HIV and AIDS Reporting System HIV in the United Kingdom: 2012 Overview.
BHIVA Clinical Audit Management of patients who switch therapy; re-audit of patients starting therapy from naïve.
Antiretroviral Treatment Monitoring: A Canadian Case Example Antiretroviral Treatment Monitoring: A Canadian Case Example Robert Hogg, PhD BC Centre for.
Impact of Highly Active Antiretroviral Therapy on the Incidence of HIV- encephalopathy among perinatally- infected children and adolescents. Kunjal Patel,
EARLY CHILDHOOD OUTCOMES AT THE BOTSWANA- BAYLOR CHILDREN’S CLINICAL CENTRE OF EXCELLENCE: A REPORT TO THE WHO TECHNICAL REFERENCE GROUP ON PEDIATRIC CARE.
Switch to second-line therapy in the CHIPS cohort Dr Kate Lee MRC Clinical Trials Unit On behalf of the Collaborative HIV Paediatric Study (CHIPS) Steering.
To overdose or underdose? The question for Kaletra in children in the UK/Irish CHIPS cohort AS Walker 1, KL Boyd 1, Menson E 2, K Butler 3, P Tookey 4,
Data from the Collaborative HIV Paediatric Study (CHIPS) Reports up to March 2010* * Numbers are based on reports received rather than children seen to.
Update on HIV Therapy Elly T Katabira, FRCP Department of Medicine Makerere University Medical School Scaling up Treatment Programs: Issues, Challenges.
Switch to DRV/r monotherapy  MONOI  MONET  PROTEA  DRV600.
The Effectiveness of generic Highly Active Antiretroviral Therapy for the treatment of HIV infected Ugandan children Presenter: Linda Barlow-Mosha MD,
Switch to LPV/r monotherapy  Pilot LPV/r  M  LPV/r Mono  KalMo  OK  OK04  KALESOLO  MOST  HIV-NAT 077.
Data from the Collaborative HIV Paediatric Study (CHIPS) Reports up to March 2006* *Numbers are based on reports received rather than children seen to.
Data from the Collaborative HIV Paediatric Study (CHIPS) Reports up to March 2012* * Numbers are based on reports received rather than children seen to.
CONCLUSIONS  Mortality and hospital admission rates continued to decline since the introduction of HAART in 1997  Viral load suppression 12 months after.
H Payne 1, K Donegan 2, I Okike 1, DM Gibb 2, K Doerholt 1, PT Heath 1 1. St Georges’ Healthcare NHS Trust 2. Clinical Trials Unit, Medical Research Council.
The DART Trial Evaluates two strategies for delivering ART, comparing: clinical monitoring only with routine laboratory + clinical monitoring structured.
Understanding temporal trends in HIV prevalence, incidence and ARV Dr Valerie Delpech Head of HIV surveillance Public Health England.
Switch to LPV/r monotherapy  Pilot LPV/r  M  LPV/r Mono  KalMo  OK  OK04  KALESOLO  MOST  HIV-NAT 077.
The case for HIV testing A presentation for the clinical team in your practice.
Atazanavir Use in Pregnancy : a report of 33 cases St George’s Hospital South West London HIV & GUM Clinical Services Network Macky Natha 1, Phillip Hay.
1 Adherence to ARV Therapy and Resistance HAIVN Havard Medical School AIDS Initiative in Vietnam.
Strategies for Management of Antiretroviral Therapy Study Wafaa El-Sadr and James Neaton for the SMART Study Team.
HIV and STI Department The case for HIV testing A presentation for the clinical team in your practice.
Morbidity, mortality, and response to treatment in HIV-infected children in the UK & Ireland : a prospective cohort study Katja Doerholt, A Judd,
Human Immune Deficiency Virus Infection Dr Huda Taha Sep 2015.
Exposure and response to highly active antiretroviral therapy (HAART) in ART naïve children in the UK and Ireland Judd A. 1, Lee K.J. 1, Duong T. 1, Walker.
1 Wide disparity in switch to second-line therapy in HIV infected children CHIPS Kate Lee MRC Clinical Trials Unit On behalf of the Collaborative HIV Paediatric.
A Call to Action Children – The missing face of AIDS.
Data from the Collaborative HIV Paediatric Study (CHIPS) Reports up to June 2015* * Numbers are based on reports received rather than children seen to.
Seroprevalence and vaccination of measles, varicella and rubella in adolescents with vertically acquired HIV infection: a multicentre audit Elgalib A 1,2,
Malignancies in Young People Sophie Herbert, Alison Barbour, Eva Jungmann, Caroline Foster on behalf of the HIV Young Persons Network (HYPNET)
HIV co-receptor tropism in treatment-naïve patients: impact on CD4 decline and subsequent response to HAART Laura Waters, Sundhiya Mandalia, Adrian Wildfire,
Switch to PI/r monotherapy
Poster 914 Effect of Tenofovir Disoproxil Fumarate (TDF) on Risk of Renal Impairment in HIV-1-infected Children on ART: Nested Case-control Study Ali Judd,
HIV+ children and young people have complex family and health contexts: results from a case note review in a London treatment centre. Tomás Campbell, Hannah.
Obstetric and paediatric HIV surveillance data from the UK and Ireland
Better Retention Rates Observed in Patients on Lopinavir than Atazanavir in Uganda
Obstetric and paediatric HIV surveillance data from the UK and Ireland
Obstetric and paediatric HIV surveillance data from the UK and Ireland
Obstetric and paediatric HIV surveillance data from the UK and Ireland
January 2014 Update Obstetric and paediatric HIV surveillance data from the UK and Ireland.
St Stephen’s Centre, Chelsea & Westminster Hospital, United Kingdom
Collaborative HIV Paediatric Study
HIV surveillance in Northern Ireland 2018
Switch to DRV/r monotherapy
Switch to LPV/r monotherapy
Switch to LPV/r monotherapy
A prospective, randomized, Phase III trial of NRTI-, PI-, and NNRTI-sparing regimens for initial treatment of HIV-1 infection – ACTG 5142 Riddler S.A.,
Switch to LPV/r monotherapy
ARV-trial.com Switch to FTC + ddI + EFV ALIZE 1.
Presentation transcript:

C Foster, A Judd, H Lyall, T Dunn, K Doerholt, P Tookey, D Gibb For Young people with perinatally acquired HIV: a Transitioning UK cohort.

Objectives To describe in adolescents (age yrs) in CHIPS : demographic clinical immunological virological ART history Resistance data

Data Collection 2006 CHIPS is a collaboration between the National Study of HIV in Pregnancy and Childhood (NSHPC), 52 clinical centres in the UK and Ireland and the MRC Clinical Trials Unit CHIPS includes all children in follow-up since 1996 in the 52 participating centres Annual prospective follow up since 2000 with prior retrospective data collection

Demographics (n=489) 489 (44%) of 1102 perinatally infected children in CHIPS are aged 10 yrs or above. Of these: 52% female 74% are of Black African origin 56% born outside the UK/Ireland Median age of presentation 1.3yr (UK born), 8.1yrs (abroad) Median duration of follow up 11yr and 5.3yrs

78%London 2% Scotland 12% Rest of England 8% Ireland Case Distribution within UK & Ireland

Presentation and “ Late presenters ” 110 (22%) presented age % with AIDS 43% mild symptoms CDC A/B 42% post diagnosis of family member 2 teenage pregnancies at antenatal screening Screen all siblings / offspring even the well teenagers

Disease Progression 9 young people died after their 10th birthday; 7 attributable to HIV, one to ARVs.

ART history * 2 received ZDV monotherapy in pregnancy *

ARVs Median length on ARVs 4.5yrs (IQR ) 78% NNRTIs 63% PIs 45% Triple class experienced 16% stopped ARVs: STI, poor adherence, refusal

Immunology and virology Median CD4 count (IQR) HIV VL <400 rna c/ml HAART start (n=375) 235 (94-468) 12% (6-19%) 6 months427 ( )174 (54%) 12 months507 ( )156 (51%) Latest follow up on HAART (n=312)225 (72%) ARV Naive (n=97)461 ( )7 (6%) At latest follow up 55 (11%) have CD4 counts <200, 74% on HAART

Resistance (Toxicity 2008) 120 (25%) young people ; total 216 assays 23 prior to HAART start: 2 had baseline NRTI mutations 97 had assays after HAART start -median 3yrs after start -85 triple class experienced 17 dual class resistance 42 triple class resistance 8.6% of cohort N=97 Wild type11 M184I/V43 NRTI other59 NNRTI64 PI major30

Transfer to adult care 67 (14%) transferred median age 17.0 yrs ( ) Median duration of follow up 10 yrs (IQR ) 40% have had an AIDS diagnosis 48% triple class experienced, 13% naive On HAART 52% had VL <400 c/ml, median CD4 296 Resistance (n=23): 8 dual, 4 triple class 25% CD4 <200 c/ml

Planning service provision Almost half of children in the CHIPS cohort have survived to adolescence BUT-1/3 have had an AIDS diagnosis -1/3 are triple class experienced -1/3 on HAART have detectable VL HOWEVER -1/5 are treatment naive -1/5 are already with you

We would like to thank the staff, families and infants from the 52 CHIPS centres CHIPS Steering Committee: Karina Butler, Katja Doerholt, David Dunn, Trinh Duong, Di Gibb, Hermione Lyall, Janet Masters, Vas Novelli, Catherine Peckham, Andrew Riordan, Mike Sharland, Pat Tookey, Gillian Wait, Gareth Tudor-Williams National Study of HIV in Pregnancy and Childhood, Institute of Child Health, London: Pat Tookey, Janet Masters, Catherine Peckham Medical Research Council Clinical Trials Unit: Di Gibb, Trinh Duong, Debbie Johnson, David Dunn, Katja Doerholt, Gill Wait, Sarah Walker We also thank the Department of Health, UK for all their support. CHIPS receives also support from Bristol Myers Squibb, Boehringer-Ingelheim, GlaxoSmithKline, Roche and Abbott & Gilead Acknowledgements

Coming to a Clinic near You Coming to a Clinic near You Be very afraid Deeply disillusioned. Complex Multidisciplinary needs. Pampered by paediatricians. Extreme attitude. Resistant virus. ‘In clinic no-one can hear you scream’. ADULTS only